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Abstract 
Use of selenium enriched foods, supplements and fertilizers has increased markedly in recent 
years in the US and other Western countries because of the perception that selenium, through 
anti-oxidant properties of selenoproteins, could potentially reduce the risk of cancer and other 
chronic diseases. However, concern has been raised recently about possible adverse cardio-
metabolic effects of high selenium exposure, such as an increased risk of diabetes and 
hyperlipidemia. Hence, from a public health perspective, the relationship between selenium 
status and cardio-metabolic health should be clarified in order to help guide consumers in their 
choices of nutritional supplements and enriched food products. Additional mechanistic evidence 
is needed to clarify the cardio-metabolic effect of selenium and selenoproteins in human biology. 
Further epidemiological studies across populations with different selenium status should be 
conducted to help determine the optimal level of selenium intake in the general population that 
maximizes the antioxidant and anti-inflammatory benefits of selenium while avoiding potential 
toxic effects. 
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Introduction 
The role of selenium in chronic disease prevention is the focus of major scientific debate and 
intensive investigation.1-2 Selenium is a key component of a number of selenoproteins involved 
in essential enzymatic functions such as redox homeostasis and thyroid hormone metabolism.3-4 
Because of the potential of selenoproteins to protect against oxidative stress, significant 
expectations were raised for the prevention of chronic diseases including cancer, cardiovascular 
disease (CVD) and type 2 diabetes,5-7 conditions commonly associated with oxidative stress.  
Indeed, early evidence from the Nutritional Prevention of Cancer (NPC) randomized trial 
suggested that selenium supplementation could prevent cancer, specifically prostate cancer, lung 
cancer and colorectal cancer, in a largely selenium-replete population in the Eastern part of the 
US.8-9  A large randomized trial of selenium supplementation in US men, however, found no 
benefit of selenium chemoprevention for prostate cancer or for other cancer endpoints.10  For 
cardiometabolic conditions, moreover, recent findings from observational studies and 
randomized clinical trials have raised concern that high selenium exposure may lead to adverse 
effects, at least in well-nourished populations.1-2,11  In the present article, we will review this 
recent evidence and discuss open questions and future perspectives in selenium research. 
 
Selenium and type 2 diabetes  
Evidence from in vivo and in vitro studies suggests that inorganic selenium can enhance insulin 
sensitivity by mediating insulin-like actions.12-13 Specifically, in animal models selenate has been 
shown to decrease the activity of protein tyrosine phosphatase, a negative regulator of insulin 
signal transmission, and can therefore potentially reduce insulin resistance.13 However, little 
information is available on insulin-like actions for forms of selenium that are more relevant for 
human exposure such as selenomethionine. Evidence from human studies on selenium and 
diabetes are conflicting. In observational studies and randomized clinical trials from selenium-
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replete populations in the US, recent findings indicate that high selenium status or selenium 
supplementation may be associated with an increased risk of type 2 diabetes.14-17 Firslyt, a large 
cross-sectional analysis within the US Third National Health and Nutrition Examination Survey 
(NHANES 1988-1994)14 showed that subjects in the highest quintile of serum selenium (137.66 
ng/ml=1.74 mol/L) had a significantly increased prevalence of diabetes compared to those in 
the lowest quintile (<111.62 ng/ml=1.41 mol/L). The positive association between serum 
selenium concentrations and the prevalence of type 2 diabetes was corroborated in a further 
analysis from NHANES 2003-2004.15 These cross-sectional studies, however, do not allow us to 
determine whether high selenium is a cause or a consequence of the disease process. Secondly, a 
post-hoc analysis of the NPC trial in the Eastern US showed that supplementation with selenium 
(200 μg/day as high-selenium yeast) compared to placebo increased the risk of type 2 diabetes,16 
particularly in men and in participants with high baseline plasma selenium (hazard ratio of 2.70 
in the highest tertile of plasma selenium, i.e. >121.6 ng/ml) (Table 1). Recently, results from the 
large Selenium and Vitamin E Cancer Prevention Trial (SELECT) in 35,533 North American 
men aged  50 y, showed a small, though non-statistically significant, increase in the number of 
cases of adult-onset diabetes in subjects supplemented with selenium alone (200 μg/day as 
selenomethionine).10 In European populations, where selenium status is generally lower than in 
the US, the evidence linking selenium to glucose metabolism is conflicting. Two small case-
control studies showed significantly lower serum selenium concentrations in patients with 
diabetes than in control subjects.17-18 This echoes the findings from a cross-sectional analysis of 
the US Health Professionals Follow-up Study that showed lower toenail selenium concentrations 
among men with diabetes (with or without CVD) than among healthy control participants.19 
Furthermore, in the EVA (Epidemiology of Vascular Ageing) study in France, plasma selenium 
concentrations were positively, though non-significantly, associated with baseline glucose levels 
in women and with prevalent diabetes in men.20 However, a recent report from the same study 
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showed that high plasma selenium (1.19-1.97 mol/L) was associated with a marginally 
significant decreased risk of onset of impaired fasting glucose or diabetes in men, but not in 
women, over the 10-year follow-up.21 Finally, in the French SU.VI.MAX (SUplémentation en 
VItamines et Minéraux AntioXydants)  trial, combined supplementation with antioxidants 
including selenium (100 µg/day as high-selenium yeast) had no effect on fasting plasma glucose 
after 7.5 y of follow-up, despite a positive association between glucose and selenium 
concentrations at baseline in the whole population.22  The explanation for these apparently 
discrepant results is still unclear. Further prospective research is needed to identify the optimal 
range of selenium intake and status in order to minimize potential adverse effects on glucose 
metabolism while optimizing type 2 diabetes prevention. 
 
Selenium and blood lipids 
Recent cross-sectional studies from unrelated populations suggest that higher selenium status is 
associated with adverse lipid profiles. Specifically, a cross-sectional analysis of serum selenium 
and lipid levels in the NHANES III (1988-1994) showed that higher serum selenium 
concentrations were associated with higher total cholesterol, LDL-cholesterol, HDL-cholesterol, 
triglycerides, apo B, and apo A1 levels.23 These findings were corroborated by a recent analysis 
from NHANES 2003-2004 showing positive associations between serum selenium 
concentrations and total, LDL- and HDL-cholesterol in a representative sample of the US 
population.24 Partly consistent with these findings, a cross-sectional analysis from the 2000-2001 
UK National Diet and Nutrition Survey (NDNS) indicated that higher selenium status was 
associated with increased total and non-HDL cholesterol, but not with increased HDL, in a 
nationally representative sample of British adults.25 In contrast to the US, a significant proportion 
of British adults are considered to have a sub-optimal intake of dietary selenium.26 Similar 
findings were also reported in a recent cross-sectional study of elderly people from Taiwan.27  
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Associations between higher selenium status and elevated total cholesterol levels have also been 
found in previous cross-sectional investigations from several populations with suboptimal 
selenium status.20,28-31  To date, there is no observational prospective evidence on the association 
of selenium status with blood lipids.  
Several randomized controlled trials in humans have evaluated the effect of selenium 
supplementation alone or in combination with other nutrients on the lipid profile. The 
SU.VI.MAX trial in a French population with sub-optimal dietary selenium intake showed that 
long-term daily supplementation with a combination of antioxidants including selenium (100 
µg/day as high-selenium yeast) increased serum triglyceride levels compared to supplementation 
with placebo. Furthermore, among those in the treatment group, women had higher total 
cholesterol levels while men were more likely to use lipid lowering medication than those on 
placebo.32 Likewise, in a randomized trial in a rural Chinese population with a low dietary intake 
of selenium, long-term combined supplementation with selenium (37.5 μg), vitamin C and 
vitamin E resulted in small but significant increases in total and LDL-cholesterol levels, though 
HDL concentrations were not affected.33   
Three relatively small randomized trials have examined the effect of selenium 
supplementation alone on the lipid profile.34-36 Two of them, conducted in Finland and China 
found no significant differences between treatment groups.34-35 In the UK, the PRECISE Pilot 
trial randomized 501 elderly volunteers of relatively low selenium status [mean (SD) plasma 
selenium 88.8 (19.2) ng/g] to a six-month treatment with 100, 200 or 300 µg selenium/d as high-
selenium yeast or placebo yeast.36 Supplementation at 100 and 200 µg selenium/d lowered total 
serum cholesterol and non-HDL cholesterol; the 300 µg/d dose had no significant effect on total 
or non-HDL cholesterol, but raised HDL-cholesterol significantly.  
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Selenium and blood pressure 
Few observational studies have evaluated the association between selenium and blood pressure 
(BP) and their findings are inconsistent. In the Flemish Study on Environment Genes and Health 
Outcomes (FLEMENGHO), higher blood selenium concentrations were associated with lower 
systolic and diastolic BP levels at baseline and with a lower risk of hypertension over 5.2 years 
of follow-up among men, though not among women.37 In a cross-sectional study conducted in 
Finland, a population with low selenium status at the time of the study, serum selenium was also 
inversely related to systolic BP levels in 722 middle-aged men.38 However, in another Finnish 
study in 1,100 elderly men, no relationship was found between BP and serum selenium 
concentration.39 Similarly, serum selenium and BP levels were not associated in a cross-sectional 
analysis of the Olivetti Heart Study among 364 southern Italian men,29 and no association  
between plasma selenium and systolic BP levels was found in the baseline EVA study.20 In the 
EVA study, however, men with hypertension had higher plasma selenium than men without 
major cardiovascular risk factors. Finally, in a recent cross-sectional analysis of serum selenium 
and hypertension in the US NHANES 2003-2004, high selenium was associated with a higher 
prevalence of hypertension in both men and women.40 The odds ratio for hypertension 
comparing the highest (≥150 µg/L) to the lowest (<122 µg/L) quintile of serum selenium was 
1.73 (1.18 to 2.53).  Unfortunately, no data are available on the effect of selenium 
supplementation on BP endpoints in randomized controlled trials using single selenium 
supplements. In the HDL-Atherosclerosis Treatment Study (HATS) trial, selenium (100 μg/d) 
was administered along with vitamin E (800 IU/d), vitamin C (1000 mg/d), and ß-carotene (25 
mg/d), with no effect on BP levels during three years of follow-up.41 In China, antioxidant 
supplementation (selenium 50 μg/d, ß-carotene 15 mg/d, and vitamin E 60 mg/d) of a 
nutritionally deficient population was linked to increased isolated diastolic hypertension, but 
other BP endpoints were not significantly different between treatment groups.42 
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Selenium and cardiovascular disease 
A number of observational studies have examined the association between selenium status and 
risk of cardiovascular disease across different populations. 43-49 Inverse associations have been 
found particularly in populations with relatively low selenium intake or status.43-47 For instance, 
in a German population of 636 patients with suspected coronary artery disease, mean plasma 
selenium was 69.5 and 74.5 μg/L at baseline in patients with and without a recurring 
cardiovascular event, respectively.45 Baseline erythrocyte glutathione peroxidase-1 (GPx-1) 
activity was a strong predictor of the risk of a subsequent cardiovascular event, over 4.7 years of 
follow-up, supporting a potential beneficial effect of selenoprotein activity on cardiovascular 
risk. In that population, selenium status was too low for GPx-1 activity to be optimised in all 
subjects.50 However, recent observational evidence in selenium-replete populations such as that 
of the US is suggestive of a possible U-shaped association (Figure 1) between selenium status 
and CVD.48-49   
Results from randomized trials of selenium supplementation do not support a role for 
selenium in cardiovascular prevention at the present time.41, 47, 51-55 Specifically, in post-hoc 
analyses from the NPC trial,55 selenium supplementation (200 μg/day as high- selenium yeast) 
was not significantly associated with any of the cardiovascular disease (CVD) endpoints after 7.6 
years of follow-up [all CVD: hazard ratio (HR) = 1.03, 95% confidence interval (CI): 0.78, 1.37; 
myocardial infarction: HR = 0.94, 95% CI: 0.61, 1.44; stroke: HR = 1.02, 95% CI: 0.63, 1.65; all 
CVD mortality: HR = 1.22, 95% CI: 0.76, 1.95].  Two other randomised trials that examined the 
effect of selenium in combination with other vitamins or minerals on CVD end points have also 
yielded null findings.53-54 
 
Potential mechanisms for cardio-metabolic effects of excessive selenium exposure 
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Evidence for mechanisms that might explain the effect of high selenium exposure on glucose and 
lipid metabolism is sparse, therefore any such discussion is highly speculative.  However, 
selenium is known to be a trace mineral with a narrow therapeutic window and considerable 
inter-individual variability in terms of metabolic sensitivity and optimal selenium intake.56-57 
Optimal intake for any individual is at least partly dependent on polymorphisms in selenoprotein 
genes that have been also shown to affect the risk of disease.2 For instance, selenoprotein 
polymorphisms have been shown to interact with selenium status to affect the risk of disease e.g. 
that of lung cancer (Jablonska et al. Eur J Nutr 2008). For instance, polymorphisms in 
the gene for the anti-inflammatory selenoprotein S (SEPS1) can affect the risk of coronary heart 
disease and ischaemic stroke, particularly in women [Alanne, Kristiansson, Auro, et al., 
Variation in the selenoprotein S gene locus is associated with coronary heart disease and 
ischemic stroke in two independent Finnish cohorts, Hum. Genet. 122 (2007) 355-65]. We know 
that polymorphisms in the gene for the anti-inflammatory selenoprotein, SEPS1, can affect the 
risk of coronary heart disease and ischaemic stroke, particularly in women. 
In animal models, the inorganic selenium species (selenate and selenite), despite some 
insulin-like properties,12-13 have been shown to impair insulin responsiveness and induce a 
catabolic response in rat muscle with glycogen depletion and increased rates of glycolysis,58 and 
to reduce insulin release from pancreatic islets in mice.59  Moreover, it has been shown that high-
selenium diets may stimulate the release of glucagon, promoting hyperglycaemia,60 or may 
induce over-expression of GPx-1 and other antioxidant selenoproteins in animal models resulting 
in the development of insulin resistance and obesity.61-63 Likewise in humans, a strongly positive 
correlation between GPx activity and insulin resistance was found in a group of non-diabetic 
pregnant women.64  In general, the toxic effects of selenium that might explain an etiologic role 
in diabetes are the capacity of some selenium compounds, notably selenite, to induce oxidative 
stress,65-67 a mechanism that is likely to play a key role in the etiology of this disease.68 However 
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the majority of food-selenium is in the form of selenomethionine, which does not have such pro-
oxidative effects.69 
 A number of sources provide evidence of a clear connection between lipoproteins and 
selenium metabolism.70-73 For example, selenoprotein P is taken up by the brain and the testes 
via the apolipoprotein E receptor-2,70-72 whereas another apolipoprotein receptor, megalin, 
mediates its uptake by the kidney.73 Moreover, in mouse knock-out models in which 
selenoprotein synthesis is compromised, both liver Apo E protein concentration, plasma 
cholesterol and expression of genes involved in cholesterol biosynthesis, metabolism and 
transport are altered, demonstrating a role for selenoproteins in the regulation of lipoprotein 
biosynthesis.74  High-dose selenium treatment of rats showed an effect on lipid metabolism, 
showing an increased total lipid content of Wistar rat heart, striatum and thalamus,75 which 
suggests the potential for sub-toxic effect of selenium supplementation at high doses. However, 
the relevance of these rat studies to humans is questionable as rats handle lipids quite 
differently.76 Furthermore, selenoprotein and cholesterol synthesis are connected through the 
common mevalonate pathway of isoprenoid biosynthesis.77 The rate-limiting enzyme in the 
mevalonate pathway, HMG CoA reductase, is inhibited by statins resulting in a lowering of 
plasma cholesterol. Moreover, recent findings from the EVA study indicated that long-term use 
of fibrates (but not statins) increased plasma selenium concentrations in dyslipidemic aged 
patients,78 which might explain, at least in part, the observed association of high selenium status 
with hyperlipidemia.  
  Altogether, the available cross-sectional evidence23-25, 27-31 linking higher selenium status 
to blood lipids is unable to determine whether lipid levels rise as a consequence of increased 
selenium intake or whether a common metabolic pathway, or common co-exposures, or reverse 
causality might explain the association between selenium status and lipid levels. However recent 
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results from the PRECISE Pilot Study suggest that the latter explanations are more probable, at 
least in populations with relatively low selenium intake or status.36 
From a mechanistic point of view, selenium intakes above the level recommended for 
optimal activity of selenoproteins, such as the glutathione peroxidases and selenoprotein P (55-
75 μg/day)79-80 will simply result in the non-specific incorporation of selenomethionine in place 
of methionine in albumin and other proteins.3 Thus mechanistically, it is unclear what advantage 
is to be gained from intakes above 75 μg/day, except perhaps in individuals having a 
selenoprotein genotype that uses selenium inefficiently for the manufacture of selenoproteins.   
 
Perspectives 
In the past few years, growing scientific attention has been focussed on the full range of effects 
of selenium status and supplementation on chronic disease endpoints. While the primary 
emphasis of selenium research has been on evaluating the potential benefits of its antioxidant and 
anticancer effects,5-9 recent findings from observational studies and randomized clinical trials 
have suggested an association between moderate to high selenium exposure and adverse cardio-
metabolic effects, at least in populations with adequate selenium intake such as the US.10-11, 14-16, 
23-24, 40  Specifically, several unrelated studies from the US indicate that high selenium status or 
selenium supplementation may be associated with an increased risk of diabetes.14-16 Furthermore, 
though not indicative of causality, recent and early cross-sectional evidence from several 
populations indicates that high selenium exposure may also be associated with an adverse lipid 
profile23-25, 27-31 and hypertension,40 raising additional concerns about sub-clinical metabolic 
toxicity of high selenium exposure and prolonged use of selenium supplements.81 It is therefore 
of concern that in the US and other Western countries the use of selenium enriched foods, 
fertilizers, and supplements has increased considerably in recent years as a result of aggressive 
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marketing26, 82-83 and despite lack of definitive evidence on their efficacy for cancer and 
cardiometabolic disease prevention.10 
Current recommendations on dietary selenium intake [55-75 µg/day]79-80 are based on 
optimizing the activity of plasma GPx, which requires a plasma selenium concentration of 92 
μg/L.50, 84-85 In the US, the mean serum selenium concentration among participants in the 
NHANES 2003-2004 was 137 g/L, and most participants (99%) had serum selenium above 95 
g/L.15, 24, 40, 49 It is therefore likely that a majority of NHANES participants would have had 
replete selenoprotein status, including that of selenoprotein P.85 Health benefits of additional 
selenium intake in such a population are therefore questionable and toxic effects, such as an 
increase in diabetes risk or adverse lipid profile, are possible. In Europe, selenium status is 
generally lower than in the US. Moreover, there is large variability in dietary selenium intakes by 
country, ranging from levels considered to be marginally adequate or adequate (Western and 
Central Europe: 30–90 µg /day) to low or deficient (Eastern European countries: 7–30 µg/day).86-
87 Therefore, the apparently puzzling evidence88-89 on the full range of effects, either beneficial or 
detrimental, of selenium exposure on chronic disease endpoints might be explained by the 
variability of selenium status and selenium dietary intakes across different countries and 
population subgroups. In this view, the association between selenium and cardio-metabolic 
outcomes is likely to be U-shaped with potential harm occurring at selenium levels both below 
and above the physiological range for optimal activity of selenoproteins.  
Additional experimental evidence is needed to provide new insights into the role of 
selenium and of specific selenoproteins in human biology, especially to clarify the underlying 
mechanisms linking selenium to chronic disease endpoints. Prospective epidemiological studies 
must be conducted to investigate the link between selenium exposure and cardiometabolic effects 
across different ranges of exposure and in different populations. This would help determine the 
optimal level of selenium intake in the general population that can maximize health benefits 
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while avoiding potential chronic toxic effects. Nevertheless, at the present time the widespread 
use of selenium supplements or other strategy that artificially increases selenium status above the 
level required for optimal selenoprotein activities for the purpose of chronic disease prevention 
should not be encouraged in populations with adequate selenium intake. 
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Table 1. Incidence of type 2 diabetes by baseline plasma selenium, Nutritional Prevention of Cancer Trial, 1983-1996 (16) 
__________________________________________________________________________________________________________________ 
  
Baseline plasma Se             Cases    Incidence*   Unadjusted     Adjusted 
      ______________        _______________     _________________________      _____________________________ 
          Se        Placebo            Se       Placebo         RRa  95% CI         P     P, M-H HRb         95% CI         P        P, intc 
__________________________________________________________________________________________________________________ 
 
By median 
 
    ≤113.4 ng/ml  26  25       11.1 10.7     1.03   0.57-1.86   0.89     0.06 1.04 0.60-1.80       0.89 0.028  
    >113.4 ng/ml  32  14       14.1   6.1     2.31   1.20-4.69   0.007  2.50 1.32-4.77       0.005 
 
By tertile 
  
   ≤105.2 ng/ml  18  18       11.6 11.3     1.03   0.50-2.09   0.92     0.21 1.13 0.58-2.18        0.72 0.038  
  105.3-121.6 ng/ml  14  10         8.8   6.5     1.35   0.56-3.40   0.46  1.36 0.60-3.09        0.63 
  >121.6 ng/ml   26  11       17.5   7.3     2.40   1.14-5.39   0.01  2.70 1.30-5.61        0.008 
 
__________________________________________________________________________________________________________________ 
*Cumulative incidence rates are per 1,000 person years 
a RR and 95% CI were derived from incidence rate ratios; Ps were derived from log-rank (P) test and Mantel-Haenszel (P, M-H) test for heterogeneity 
b HR, 95% CI, and Ps from the Cox proportional hazards model adjusted for age, BMI, smoking status and gender 
c P for treatment group characteristic interaction is for the (treatment group x factor) cross-product term in separate Cox proportional hazards model 
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Figure 1: Cardiovascular Disease Mortality and Serum Selenium Levels. NHANES III, 1988-1994 (48)   
 
